AWM Investment Company Inc. bought a new position in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 106,435 shares of the company's stock, valued at approximately $462,000. AWM Investment Company Inc. owned approximately 0.21% of Cardiff Oncology at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of the business. Shay Capital LLC acquired a new position in Cardiff Oncology in the fourth quarter worth $91,000. Point72 Asset Management L.P. acquired a new position in Cardiff Oncology during the 4th quarter worth about $2,207,000. ProShare Advisors LLC bought a new stake in Cardiff Oncology during the 4th quarter worth about $50,000. Nuveen Asset Management LLC increased its position in Cardiff Oncology by 73.7% in the 4th quarter. Nuveen Asset Management LLC now owns 586,616 shares of the company's stock valued at $2,546,000 after acquiring an additional 248,850 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new stake in Cardiff Oncology in the 4th quarter valued at about $6,677,000. 16.29% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Separately, HC Wainwright upped their target price on shares of Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, May 9th.
Get Our Latest Research Report on CRDF
Cardiff Oncology Trading Up 5.2%
Shares of NASDAQ:CRDF traded up $0.15 during midday trading on Monday, hitting $3.03. The company had a trading volume of 1,306,373 shares, compared to its average volume of 1,136,207. The firm has a fifty day simple moving average of $2.92 and a 200 day simple moving average of $3.44. The stock has a market cap of $201.57 million, a price-to-earnings ratio of -3.22 and a beta of 1.81. Cardiff Oncology, Inc. has a 12 month low of $2.01 and a 12 month high of $5.64.
Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.09 million. Equities analysts forecast that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.
Cardiff Oncology Profile
(
Free Report)
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Featured Stories
Before you consider Cardiff Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiff Oncology wasn't on the list.
While Cardiff Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
